1
|
Ribeiro M, Oderich GS, Macedo T, Vrtiska TJ, Hofer J, Chini J, Mendes B, Cha S. Assessment of aortic wall thrombus predicts outcomes of endovascular repair of complex aortic aneurysms using fenestrated and branched endografts. J Vasc Surg 2017; 66:1321-1333. [PMID: 28596039 DOI: 10.1016/j.jvs.2017.03.428] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 03/21/2017] [Indexed: 11/28/2022]
Abstract
OBJECTIVE The goal of this study was to investigate the correlation between atherothrombotic aortic wall thrombus (AWT) and clinical outcomes in patients treated by fenestrated-branched endovascular aortic repair (F-BEVAR) and present a new classification system for assessment of AWT burden. METHODS The clinical data of 301 patients treated for pararenal and thoracoabdominal aortic aneurysms (TAAAs) by F-BEVAR was reviewed. The study excluded 89 patients with extent I to III TAAA because of extensive laminated thrombus within the aneurysm sac. Computed tomography angiograms were analyzed in all patients to determine the location, extent, and severity of atherothrombotic AWT. The aorta was divided into three segments: ascending and arch (A), thoracic (B) and renal-mesenteric (C). Volumetric measurements (cm3) of AWT were performed using TeraRecon software (TeraRecon Inc, Foster City, Calif). These volumes were used to create an AWT index by dividing the AWT volume from the total aortic volume. A classification system was proposed using objective assessment of the number of affected segments, thrombus type, thickness, area, and circumference. Clinical outcomes included 30-day mortality, neurologic and gastrointestinal complications, renal events (Risk, Injury, Failure, Loss of kidney function, End-stage renal disease [RIFLE]), and solid organ infarction. RESULTS The study included 212 patients, 169 men (80%) and 43 women (20%), with a mean age of 76 ± 7 years. A total of 700 renal-mesenteric arteries were incorporated (3.1 ± 1 vessels/patient). AWT was classified as mild in 98 patients (46%) and was considered moderate or severe in 114 (54%). There was one death (0.5%) at 30 days. Solid organ infarction was present in 50 patients (24%), and acute kidney injury occurred in 45 patients (21%) by RIFLE criteria. An association with higher AWT indices was found for time to resume enteral diet (P = .0004) and decline in renal function (P = .0003). Patients with acute kidney injury 2 by RIFLE criterion had significantly higher (P = .002) AWT index scores in segment B. Spinal cord injury occurred in three patients (1.4%) and stroke in four (1.9%), but were not associated with the AWT index. Severity of AWT using the new proposed classification system correlated with the AWT index in all three segments (P < .001). Any of the end points occurred in 35% of the patients with mild and in 53% of those with moderate or severe AWT (P = .016). CONCLUSIONS AWT predicts solid organ infarction, renal function deterioration, and longer time to resume enteral diet after F-BEVAR of pararenal and type IV TAAAs. Evaluation of AWT should be part of preoperative planning and decision making for selection of the ideal method of treatment in these patients.
Collapse
Affiliation(s)
- Mauricio Ribeiro
- Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn; Division of Vascular and Endovascular Surgery, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Gustavo S Oderich
- Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
| | | | | | - Jan Hofer
- Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn
| | - Julia Chini
- Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn
| | - Bernardo Mendes
- Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn
| | - Stephen Cha
- Department of Epidemiology and Biostatistics, Mayo Clinic, Rochester, Minn
| |
Collapse
|
2
|
A case of atherosclerotic renal artery stenosis involving successful withdrawal from hemodialysis after percutaneous transluminal renal artery stenting. Int J Cardiol 2016; 223:669-671. [PMID: 27568986 DOI: 10.1016/j.ijcard.2016.08.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 08/03/2016] [Indexed: 11/22/2022]
|
3
|
Patel SM, Li J, Parikh SA. Renal Artery Stenosis: Optimal Therapy and Indications for Revascularization. Curr Cardiol Rep 2016; 17:623. [PMID: 26238738 DOI: 10.1007/s11886-015-0623-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Atherosclerotic renal artery stenosis (ARAS) is associated with increased cardiovascular risk and overall mortality. Manifestations of ARAS include resistant or malignant hypertension, progressive deterioration of renal function, and cardiac dysfunction syndromes of flash pulmonary edema and angina. Diagnosis rests upon non-invasive studies such as duplex ultrasonography and is confirmed using invasive renal arteriography. Regardless of the severity of ARAS, management of this entity has been a topic of contentious debate. For over two decades, the use of percutaneous revascularization to treat ARAS has been studied with various clinical trials. Though case series seem to demonstrate favorable clinical response to revascularization, the overwhelming majority of randomized clinical trials have not mirrored a robust outcome. In these trials, poor correlation is noted between the reduction of stenosis and the improvement of renovascular hypertension and glomerular filtration rate, and decrease in cardiovascular outcomes and mortality. With dichotomizing results, the explanation for these discrepant findings has been attributed to improper trial design and inappropriate patient selection. An overview of the treatment options available will be provided, with a focus on the methodology and design of clinical trials investigating the efficacy of percutaneous revascularization. Emphasis is placed on appropriate patient selection criteria, which may necessitate the use of hemodynamic lesion assessment and clinical correlation based on individualized care. When clinical equipoise exists between optimal medical therapy and revascularization, the current paradigm supports ongoing medical therapy as the treatment of choice. However, renal artery stenting remains a viable therapeutic option for those who continue to have clinical syndromes consistent with renal hypoperfusion while adequately treated with optimal medical therapy. Despite observational studies suggesting clinical benefit for this specific patient population, there remains a paucity of randomized clinical trial data. Further trials targeting the patients who are inadequately treated with optimal medical therapy need to be undertaken to confirm the efficacy of revascularization.
Collapse
Affiliation(s)
- Sandeep M Patel
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | | | | |
Collapse
|
4
|
Campbell JE, Stone PA, Bates MC. Technical discussion of diagnostic angiography and intervention of atherosclerotic renal artery stenosis. Semin Vasc Surg 2014; 26:150-60. [PMID: 25220320 DOI: 10.1053/j.semvascsurg.2014.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Renal artery stenting remains an important adjuvant treatment for true-resistant hypertension, although recent disappointing randomized trials highlight the importance of careful patient selection. Safe and successful renal interventions begin with critical core knowledge regarding renal artery anatomy and understanding the often hostile nature of the parent vessel (pararenal aorta). Armed with fundamental knowledge about anatomy and renal ostial disease pathology, it becomes easier to understand the advantages of less traumatic access techniques and how low-profile contemporary flexible stents have enhanced outcomes. In addition to suggested techniques based on detailed understanding of the vessel architecture and pathology, we will review the current available US Food and Drug Administration-approved balloon-expandable on-label renal stents and discuss the role of intravascular ultrasound for definition of lesion severity, stent sizing, and stent apposition. The durability of renal stenting will also be discussed, as will the velocity criteria for duplex surveillance. Lastly, the current empirical data related to renal embolic protection is provided, along with insight into technical issues in this domain.
Collapse
Affiliation(s)
- John E Campbell
- Department of Surgery, West Virginia University Division of Vascular and Endovascular Surgery, Vascular Center of Excellence, Charleston Area Medical Center, 3100 MacCorkle Avenue SE, Charleston, West Virginia 25304.
| | - Patrick A Stone
- Department of Surgery, West Virginia University Division of Vascular and Endovascular Surgery, Vascular Center of Excellence, Charleston Area Medical Center, 3100 MacCorkle Avenue SE, Charleston, West Virginia 25304
| | - Mark C Bates
- Department of Surgery, West Virginia University Division of Vascular and Endovascular Surgery, Vascular Center of Excellence, Charleston Area Medical Center, 3100 MacCorkle Avenue SE, Charleston, West Virginia 25304
| |
Collapse
|
5
|
Marshall RH, Schiffman MH, Winokur RS, Talenfeld AD, Siegel DN. Interventional Radiologic Techniques for Screening, Diagnosis and Treatment of Patients with Renal Artery Stenosis. Curr Urol Rep 2014; 15:414. [DOI: 10.1007/s11934-014-0414-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Christie JW, Conlee TD, Craven TE, Hurie JB, Godshall CJ, Edwards MS, Hansen KJ. Early duplex predicts restenosis after renal artery angioplasty and stenting. J Vasc Surg 2012; 56:1373-80; discussion 1380. [PMID: 23083664 DOI: 10.1016/j.jvs.2012.05.067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Revised: 05/09/2012] [Accepted: 05/09/2012] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To examine the relationship between early renal duplex sonography (RDS) and restenosis after primary renal artery percutaneous angioplasty and stenting (RA-PTAS). METHODS Consecutive patients undergoing RA-PTAS for hemodynamically significant atherosclerotic renal artery stenosis with hypertension and/or ischemic nephropathy between September 2003 and July 2010 were identified from a prospective registry. Patients had renal RDS pre-RA-PTAS, within 1 week of RA-PTAS and follow-up RDS examinations after the first postoperative week for surveillance of restenosis. Restenosis was defined as a renal artery peak systolic velocity (PSV) ≥ 180 cm/s on follow-up RDS. Associations between RDS and restenosis were examined using proportional hazards regression. RESULTS Eighty-three patients (59% female; 12% nonwhite; mean age, 70 ± 10 years; mean pre-RA-PTAS PSV, 276 ± 107 cm/s) undergoing 91 RA-PTAS procedures comprised the sample for this study. All procedures included a completion arteriogram demonstrating no significant residual stenosis. Mean follow-up time was 14.9 ± 10.8 months. Thirty-four renal arteries (RAs) demonstrated restenosis on follow-up with a median time to restenosis of 8.7 months. There was no significant difference in the mean PSV pre-RA-PTAS in those with and without restenosis (287 ± 96 cm/s vs 269 ± 113 cm/s; P = .455), and PSV pre-RA-PTAS was not predictive of restenosis. Within 1 week of RA-PTAS, mean renal artery PSV differed significantly for renal arteries with and without restenosis (112 ± 27 cm/s vs 91 ± 34 cm/s; P = .003). Proportional hazards regression analysis demonstrated increased PSV on first post-RA-PTAS RDS was significantly and independently associated with subsequent restenosis during follow-up (hazard ratio for 30 cm/s increase, 1.81; 95% confidence interval, 1.32-2.49; P = .0003). There was no difference in pre- minus postprocedural PSV in those with and without restenosis on follow-up (175 ± 104 cm/s vs 179 ± 124 cm/s; P = .88), nor was this associated with time to restenosis. Best subsets model selection identified first postprocedural RDS as the only factor predictive of follow-up restenosis. A receiver-operating characteristic curve was examined to assess the first week PSV post-RA-PTAS most predictive of restenosis during follow-up. The ideal cut point for RA-PSV was 87 cm/s or greater. This value was associated with a sensitivity of 82.4%, specificity of 52.6%, and area under the receiver-operating characteristic curve of 69.3%. Increased first postprocedural RA-PSV was predictive of lower estimated glomerular filtration rate in the first 2 years after the procedure (-1.6 ± 0.7 mL/min/1.73 m(2) lower estimated glomerular filtration rate per 10 cm/s increase in RA-PSV; P = .010). CONCLUSIONS Early renal artery PSV within 1 week after RA-PTAS predicted renal artery restenosis and lower postprocedure renal function. Recurrent stenosis demonstrated no association with absolute elevation in PSV prior to RA-PTAS nor with the change in PSV after RA-PTAS. These data suggest that detectable differences exist in renal artery flow parameters following RA-PTAS that are predictive of restenosis during follow-up but are not apparent on completion arteriography or detectable by intra-arterial pressure measurements. Further study is warranted.
Collapse
Affiliation(s)
- Jason W Christie
- Department of Vascular and Endovascular Surgery, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157-1095, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Khosla A, Misra S, Greene EL, Pflueger A, Textor SC, Bjarnason H, McKusick MA. Clinical outcomes in patients with renal artery stenosis treated with stent placement with embolic protection compared with those treated with stent alone. Vasc Endovascular Surg 2012; 46:447-54. [PMID: 22692467 DOI: 10.1177/1538574412449911] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE To compare the clinical outcomes in patients with chronic renal insufficiency (CRI) and renal artery stenosis (RAS) following renal artery (RA) stent placement with and without embolic protection device (EPD) usage. MATERIALS AND METHODS Eighteen patients who had RA stent placement with EPD were matched to control patients (RA stent only). Blood pressure, number of hypertensive medications, and estimated glomerular filtration rate (eGFR) at 3 months before the procedure and after 12 months were determined. An increase of ≥ 20% in eGFR at 12 months from baseline was defined as "improvement," decrease of ≥ 20% as "deterioration," and an eGFR change between those values as "stabilization" at 12 months. RESULTS At 12 months, stage 4 patients treated with EPD had significantly higher eGFR than controls (P = .01). There was no statistical difference in blood pressure outcomes between the 2 groups. CONCLUSIONS Patients with stage 4 CRI did significantly better with EPD than those treated without it.
Collapse
Affiliation(s)
- Ankaj Khosla
- Department of Radiology, School of Medicine, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Patel PM, Kern MJ. Moving renal embolic protection forward. Catheter Cardiovasc Interv 2012; 79:437-8. [PMID: 22328234 DOI: 10.1002/ccd.24313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
9
|
Modrall JG, Timaran CH, Rosero EB, Chung J, Plummer M, Valentine RJ, Trimmer C. Longitudinal changes in kidney parenchymal volume associated with renal artery stenting. J Vasc Surg 2012; 55:774-80; discussion 780. [PMID: 22264697 DOI: 10.1016/j.jvs.2011.10.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2011] [Revised: 10/10/2011] [Accepted: 10/11/2011] [Indexed: 11/17/2022]
Abstract
OBJECTIVE This study assessed the longitudinal changes in renal volume after renal artery stenting (RAS) to determine if renal mass is preserved by stenting. METHODS The study cohort consisted of 38 patients with longitudinal imaging available for renal volume quantification before and after RAS. Renal volume was estimated as (kidney length) × (width) × (depth/2) based on preoperative renal imaging. For each patient, the clinical response of blood pressure (BP) and renal function to RAS was categorized according to modified American Heart Association guidelines. Changes in renal volume were assessed using paired nonparametric analyses. RESULTS The cohort was a median age of 69 years (interquartile range [IQR], 60-74 years). A favorable BP response was observed in 11 of 38 patients (28.9%). At a median interval between imaging studies of 21 months (IQR, 13-32 months), ipsilateral renal volume was significantly increased from baseline (146.8 vs 133.8 cm(3);P = .02). This represents a 6.9% relative increase in ipsilateral kidney volume from baseline. A significant negative correlation between preoperative renal volume and the relative change in renal volume postoperatively (r = -0.42; P = .0055) suggests that smaller kidneys experienced the greatest gains in renal volume after stenting. It is noteworthy that the 25 patients with no change in BP or renal function-clinical failures using traditional definitions-experienced a 12% relative increase in ipsilateral renal volume after RAS. Multivariate analysis determined that stable or improved renal volume after stenting was an independent predictor of stable or improved long-term renal function (odds ratio, 0.008; 95% confidence interval, 0.000-0.206; P = .004). CONCLUSIONS These data lend credence to the belief that RAS preserves renal mass in some patients. This benefit of RAS even extends to those patients who would be considered treatment failures by traditional definitions. Patients with stable or increased renal volume after RAS had more stable renal function during long-term follow-up, whereas patients with renal volume loss after stenting were prone to deterioration of renal function.
Collapse
|
10
|
Laird JR, Tehrani F, Soukas P, Joye JD, Ansel GM, Rocha-Singh K. Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis. Catheter Cardiovasc Interv 2011; 79:430-6. [PMID: 21805607 DOI: 10.1002/ccd.23292] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Accepted: 06/25/2011] [Indexed: 11/08/2022]
Affiliation(s)
- John R Laird
- The Division of Cardiovascular Medicine and the Vascular Center, UC Davis Medical Center, Sacramento, California 95817, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Modrall JG, Rosero EB, Timaran CH, Anthony T, Chung J, Valentine RJ, Trimmer C. Assessing outcomes to determine whether symptoms related to hypertension justify renal artery stenting. J Vasc Surg 2011; 55:413-9; discussion 419-20. [PMID: 22133456 DOI: 10.1016/j.jvs.2011.08.056] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2011] [Revised: 08/30/2011] [Accepted: 08/30/2011] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The goal of the study was to determine the blood pressure (BP) response to renal artery stenting (RAS) for patients with hypertension urgency, hypertension emergency, and angina with congestive heart failure (angina/congestive heart failure [CHF]). METHODS Patients who underwent RAS for hypertension emergencies (n = 13), hypertension urgencies (n = 25), and angina/CHF (n = 14) were included in the analysis. By convention, hypertension urgency was defined by a sustained systolic BP ≥ 180 mm Hg or diastolic BP ≥ 120 mm Hg, while the definition of hypertension emergency required the same BP parameters plus hypertension-related symptoms prompting hospitalization. Patient-specific response to RAS was defined according to modified American Heart Association reporting guidelines. RESULTS The study cohort of 52 patients had a median age of 66 years (interquartile range 58-72). The BP response to RAS varied significantly according to the indication for RAS. Hypertension emergency provided the highest BP response rate (85%), while the response rate was significantly lower for hypertension urgency (52%) and angina/CHF (7%; P = .03). Only 1 of 14 patients with angina/CHF was a BP responder. Multivariate analysis showed that hypertension urgency or emergency were not independent predictors of BP response to RAS. Instead, the only independent predictor of a favorable BP response was the number of preoperative antihypertensive medications (odds ratio 7.5; 95% confidence interval 2.5-22.9; P = .0004), which is another indicator of the severity of hypertension. Angina/CHF was an independent predictor of failure to respond to RAS (odds ratio 118.6; 95% confidence interval 2.8-999.9; P = .013). CONCLUSIONS Hypertension urgency and emergency are clinical manifestations of severe hypertension, but the number of preoperative antihypertensive medications proved to be a better predictor of a favorable BP response to RAS. In contrast, angina/CHF was a predictor of failure to respond to stenting, providing further evidence against the practice of incidental stenting during coronary interventions.
Collapse
Affiliation(s)
- J Gregory Modrall
- Dallas Veterans Affairs Medical Center, University of Texas Southwestern Medical School, Dallas, TX, USA.
| | | | | | | | | | | | | |
Collapse
|
12
|
Modrall JG, Timaran CH, Rosero EB, Chung J, Arko FA, Valentine RJ, Clagett GP, Trimmer C. Predictors of outcome for renal artery stenting performed for salvage of renal function. J Vasc Surg 2011; 54:1414-1421.e1; discussion 1420-1. [DOI: 10.1016/j.jvs.2011.04.042] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Revised: 04/14/2011] [Accepted: 04/14/2011] [Indexed: 10/17/2022]
|
13
|
Abstract
Renal artery stenosis (RAS) is the most commonly caused by atherosclerosis, with fibromuscular dysplasia being the most frequent among other less common etiologies. A high index of suspicion based on clinical features is essential for diagnosis. Revascularization strategies are currently a topic of discussion and debate. When revascularization is deemed appropriate, atherosclerotic RAS is most often treated with stent placement, whereas patients with fibromuscular dysplasia are usually treated with balloon angioplasty. Ongoing randomized trials should help to better define the optimal management of RAS.
Collapse
|
14
|
Abstract
Some degree of distal embolization likely occurs during all transcatheter interventional procedures. The clinical sequela is defined by the sensitivity of the target organ to segmental ischemia and the burden of embolic load. The spectrum of clinical consequences varies from the extremes of stroke and no-reflow phenomena in the carotid and coronaries, respectively, to silent renal insult following renal stenting. The clinical sequela of stroke and myocardial infarction in these most sensitive end-organ distributions led to the birth of embolic protection science. Over the past 2 decades embolic protection has matured and we now have a menu of devices to consider based on our specific patient clinical and anatomic needs. The goal of this narrative is to provide an update on protection device science and, more importantly, a very practical informal guide to the currently available technologies with emphasis on the pitfalls common to specific device families.
Collapse
Affiliation(s)
- Mark C Bates
- Department of Surgery, West Virginia University School of Medicine, Charleston, WV 25304, USA.
| | | |
Collapse
|
15
|
Abstract
Renovascular diseases are common conditions with important implications on cardiovascular morbidity and mortality. Renal artery stenosis (RAS) is present in 1-5% of patients with hypertension (HTN) in the US with the vast majority of caused by atherosclerosis. Atherosclerotic RAS is related not only to uncontrolled HTN, but also to renal dysfunction. Atherosclerotic RAS in the USA has been reported to account for approximately 14-16% of new patients requiring dialysis each year. Hence a concerted effort was made in the last decade to treat renovascular stenosis using newly developed endovascular therapies to improve cardiovascular morbidity and renal function. A review on new advances in the endovascular management of renal artery stenosis with low profile stents, embolic protection devices, and drug eluting stents is presented.
Collapse
|
16
|
Colyer WR, Cooper CJ. Management of Renal Artery Stenosis: 2010. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2011; 13:103-13. [DOI: 10.1007/s11936-011-0111-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Kanjwal K, Cooper CJ, Virmani R, Haller S, Shapiro JI, Burket MW, Steffes M, Brewster P, Zhang H, Colyer WR. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheter Cardiovasc Interv 2010; 76:16-23. [PMID: 20209644 DOI: 10.1002/ccd.22469] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVE The objective of this study was to identify the predictors of distal embolization (DE) during protected renal artery angioplasty and stenting. BACKGROUND DE may contribute to worsening renal function after renal artery stenting. The factors associated with DE, rates of platelet-rich emboli, and treatments that may prevent DE during renal stenting have not been evaluated. METHODS The current study evaluated patients randomized to receive an embolic protection device (EPD) in the RESIST trial. Forty-two patients were identified for inclusion in this study. These patients were further randomized to abciximab (N = 22) or placebo (N = 20). Modification in Diet in Renal Disease glomerular filtration rate (GFR) was used as the primary measure of renal function. Creatinine was measured by a modified Jaffe reaction using the IDMS-traceable assay. The primary endpoint was capture of platelet rich emboli in the angioguard basket. RESULTS DE occurred in 15/42 (35%) of the patients and platelet rich DE in 10 (24%) of the patients who received an EPD. Of the angiographic characteristics only lesion length was significantly higher in patients with DE (16 +/- 7 mm vs. 10 +/- 5 mm, P = 0.04). Preprocedural abciximab reduced DE from 42 to 8% (P = 0.02). The rate of platelet rich emboli was 50% with neither abciximab nor a thienopyridine, 36% with thienopyridine only, 15% abciximab only, and 0% in patients who received both a thienopyridine and abciximab. Only Abciximab use was associated with improved renal function at 1-month, thienopyridine was not. Angiographic characteristics including percent stenosis, minimal luminal diameter (MLD), reference diameter, change in MLD, contrast volume, and procedure time were not predictors of DE during renal stenting. CONCLUSION Capture of DE and specifically platelet DE are common during protected renal stenting using a filter-type EPD. Abciximab use, and potentially combined thienopyridine and abciximab use, decreased the rate of platelet rich DE; however, only abciximab improved renal function at 1-month.
Collapse
Affiliation(s)
- Khalil Kanjwal
- Department of Medicine, Division of Cardiology, The University of Toledo, 3000 Arlington Ave., Toledo, OH 43614, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Henry M, Henry I, Polydorou A, Hugel M. Renal angioplasty stenting under embolic protection device: first human study with the FiberNet™ 3D filter. Interv Cardiol 2010. [DOI: 10.2217/ica.10.62] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
19
|
Affiliation(s)
- Christopher J White
- Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA.
| |
Collapse
|
20
|
|
21
|
Davies MG, Saad WE, Bismuth J, Naoum JJ, Peden EK, Lumsden AB. Renal parenchymal preservation after percutaneous renal angioplasty and stenting. J Vasc Surg 2010; 51:1222-9; discussion 1229. [PMID: 20138728 DOI: 10.1016/j.jvs.2009.09.050] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Revised: 09/15/2009] [Accepted: 09/21/2009] [Indexed: 10/19/2022]
Abstract
BACKGROUND The intent of endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is to preserve parenchyma and avoid renal-related morbidity. The aim of this study is to examine the impact of renal artery intervention on parenchymal preservation. METHODS We performed a retrospective analysis of records from patients who underwent endovascular intervention for ARAS and were followed by duplex ultrasound between 1990 and 2008. Renal volume (in cm(3)) was estimated in all patients as renal length (cm) x renal width (cm) x renal depth (cm) x 0.5. The normal renal volume was calculated as 2 x body weight (kg) in cm(3). Failure of preservation was considered to be a persistent 10% decrease in volume. Clinical benefit defined as freedom from renal-related morbidity (increase in persistent creatinine >20% of baseline, progression to hemodialysis, death from renal-related causes) was calculated. RESULTS Five hundred ninety-two renal artery interventions were performed. One hundred eighty-six kidneys suffered parenchymal loss (>5%) with an actuarial parenchymal loss rate of 29% +/- 1% at five years respectively. There were no significant differences in age, gender, starting renal volume, or kidney size. However, patients with parenchymal loss had lower eGFR (45 +/- 24 vs 53 +/- 24 mL/min/1.73 m(2); Loss vs noLoss, P = .0002, Mean +/- SD) higher resistive index (0.75 +/- 0.9 vs 0.73 +/- 0.10; P = .0001) and worse nephrosclerosis grade (1.43 +/- 0.55 vs 1.30 +/- 0.49; P = .006) then those not suffering parenchymal loss. Parenchymal loss was associated with significantly worse five-year survival (26% +/- 4% vs 48% +/- 2%; Loss vs noLoss; P < .001) and freedom from renal-related morbidity (70% +/- 5% vs 82% +/- 2%; P < .05) with increased numbers progressing to dialysis (17% vs 7%; P < .006). CONCLUSION While parenchymal preservation occurs in most patients, parenchymal loss occurs in 31% of patients and is associated with markers of impaired parenchymal perfusion (resistive index and nephrosclerosis grade) at the time of intervention. Pre-existing renal size or volumes were not predictive of parenchymal loss. Parenchymal loss is associated with a significant decrease in survival and a marked increased renal related morbidity and progression to hemodialysis.
Collapse
Affiliation(s)
- Mark G Davies
- Department of Cardiovascular Surgery, Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, Tex, USA.
| | | | | | | | | | | |
Collapse
|
22
|
White CJ. Management of renal artery stenosis: the case for intervention, defending current guidelines, and screening (drive-by) renal angiography at the time of catheterization. Prog Cardiovasc Dis 2010; 52:229-37. [PMID: 19917334 DOI: 10.1016/j.pcad.2009.09.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
There is little debate that an untreated significant obstruction of blood flow to the kidney, most often due to atherosclerosis, is potentially hazardous to the health of patients. The treatment of atherosclerotic renovascular disease has evolved over the past 20 years from open surgery with its inherent morbidity and risk of mortality to percutaneous endovascular treatment with stents. The current debate is on the question of which patients are offered any additional advantage by revascularization for renal artery stenosis over medications alone. The primary issue is patient selection, including the most appropriate screening strategies for renal artery stenosis, which must be balanced against the risk of procedure-related complications. The goal of this paper is to explore the most appropriate utilization of revascularization with renal stent placement.
Collapse
Affiliation(s)
- Christopher J White
- John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
| |
Collapse
|
23
|
Allaqaband S, Kirvaitis R, Jan F, Bajwa T. Endovascular treatment of peripheral vascular disease. Curr Probl Cardiol 2009; 34:359-476. [PMID: 19664498 DOI: 10.1016/j.cpcardiol.2009.05.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Peripheral arterial disease (PAD) affects about 27 million people in North America and Europe, accounting for up to 413,000 hospitalizations per year with 88,000 hospitalizations involving the lower extremities and 28,000 involving embolectomy or thrombectomy of lower limb arteries. Many patients are asymptomatic and, among symptomatic patients, atypical symptoms are more common than classic claudication. Peripheral arterial disease also correlates strongly with risk of major cardiovascular events, and patients with PAD have a high prevalence of coexistent coronary and cerebrovascular disease. Because the prevalence of PAD increases progressively with age, PAD is a growing clinical problem due to the increasingly aged population in the United States and other developed countries. Until recently, vascular surgical procedures were the only alternative to medical therapy in such patients. Today, endovascular practice, percutaneous transluminal angioplasty with or without stenting, is used far more frequently for all types of lower extremity occlusive lesions, reflecting the continuing advances in imaging techniques, angioplasty equipment, and endovascular expertise. The role of endovascular intervention in the treatment of limb-threatening ischemia is also expanding, and its promise of limb salvage and symptom relief with reduced morbidity and mortality makes percutaneous transluminal angioplasty/stenting an attractive alternative to surgery and, as most endovascular interventions are performed on an outpatient basis, hospital costs are cut considerably. In this monograph we discuss current endovascular intervention for treatment of occlusive PAD, aneurysmal arterial disease, and venous occlusive disease.
Collapse
|
24
|
Anchala PR, Resnick SA. The current state of endovascular therapy in the evaluation and management of renovascular disease. Semin Intervent Radiol 2009; 26:333-44. [PMID: 21326543 DOI: 10.1055/s-0029-1242202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Hypertension is the most common reason for physician office visits among nonpregnant adults in the United States; up to one-third of Americans over the age of 18 have been diagnosed with hypertension. Patients with physiologically significant renal artery stenosis often go unnoticed because hypertension can often be well controlled with antihypertensive medications. As a result, screening for renovascular causes of hypertension is rarely done. However, the likelihood of renovascular disease increases in patients with acute, severe, or refractory hypertension and should be explored in patients who fall into these categories. Renovascular disease is a crucial consideration in the management of hypertension due to its increasing incidence and its potential for reversibility. Although renovascular disease accounts for less than 1% of patients with mild hypertension, it is estimated that between 10 and 45% of white patients with severe or malignant hypertension have renal artery stenosis (RAS). In this population, diagnosing and treating RAS can have a profound and long-lasting effect on the treatment of hypertension.
Collapse
Affiliation(s)
- Praveen R Anchala
- Department of Interventional Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | |
Collapse
|
25
|
Contemporary management of atherosclerotic renovascular disease. J Vasc Surg 2009; 50:1197-210. [DOI: 10.1016/j.jvs.2009.05.048] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2009] [Revised: 05/15/2009] [Accepted: 05/17/2009] [Indexed: 01/13/2023]
|
26
|
Diagnosis and management of atherosclerotic renal artery stenosis: improving patient selection and outcomes. Nat Rev Cardiol 2009; 6:176-90. [PMID: 19234498 DOI: 10.1038/ncpcardio1448] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2008] [Accepted: 12/04/2008] [Indexed: 01/02/2023]
Abstract
Renal artery stenosis (RAS) is common among patients with atherosclerosis, and is found in 20-30% of individuals who undergo diagnostic cardiac catheterization. Renal artery duplex ultrasonography is the diagnostic procedure of choice for screening outpatients for RAS. Percutaneous renal artery stent placement is the preferred method of revascularization for hemodynamically significant RAS, and is favored over balloon angioplasty alone. Stent placement carries a class I recommendation for atherosclerotic RAS according to ACC and AHA guidelines. Discordance exists between the very high (>95%) procedural success rate and the moderate (60-70%) clinical response rate after renal stent placement, which is likely to be a result of poor selection of patients, inadequate angiographic assessment of lesion severity, and the presence of renal parencyhmal disease. Physiologic lesion assessment using translesional pressure gradients, and measurements of biomarkers (e.g. brain natriuretic peptide), or both, could enhance the selection of patients and improve clinical response rates. Long-term patency rates for renal stenting are excellent, with 5-year secondary patency rates greater than 90%. This Review will outline the clinical problem of atherosclerotic RAS and its diagnosis, and will critically assess treatment options and strategies to improve patients' outcomes.
Collapse
|
27
|
Corriere MA, Edwards MS, Pearce JD, Andrews JS, Geary RL, Hansen KJ. Restenosis after renal artery angioplasty and stenting: incidence and risk factors. J Vasc Surg 2009; 50:813-819.e1. [PMID: 19595532 DOI: 10.1016/j.jvs.2009.05.019] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2009] [Revised: 05/07/2009] [Accepted: 05/12/2009] [Indexed: 01/08/2023]
Abstract
BACKGROUND Management of renal artery stenosis (RAS) with primary renal artery percutaneous angioplasty and stenting (RA-PTAS) is associated with a low risk of periprocedural death and major complications; however, restenosis develops in a subset of patients and repeat intervention may be required. We examined the incidence of restenosis after RA-PTAS and associations with clinical factors. METHODS Consecutive patients undergoing RA-PTAS for hemodynamically significant atherosclerotic RAS associated with hypertension or ischemic nephropathy, or both, between October 2003 and September 2007 were identified from a registry. Restenosis was defined using duplex ultrasound (DUS) imaging as a renal artery postintervention peak systolic velocity (PSV) >or=180 cm/s. The incidence and temporal distribution of restenosis was analyzed using survival analysis based on treated kidneys. Associations between clinical factors and recurrent stenosis were examined using proportional hazards regression. RESULTS RA-PTAS was performed on 112 kidneys for atherosclerotic RAS during the study period. Initial postintervention renal artery DUS imaging confirming PSV <180 cm/s in 101 kidneys, which formed the basis of this analysis. Estimated restenosis-free survival was 50% at 12 months and 40% at 18 months. Decreased risk of restenosis was associated with preoperative statin use (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.16-0.74; P = .006) and increased preoperative diastolic blood pressure (DBP; HR, 0.70 per 10-mm Hg increase in preoperative DBP; 95% CI, 0.49-0.99; P = .049). No other factors assessed were associated with restenosis. CONCLUSION Restenosis occurs in a substantial number of patients treated with RA-PTAS. Preoperative statin medication use and increased preoperative DBP are associated with reduced risk of restenosis. In the absence of contraindications, statins should be considered standard therapy for patients with atherosclerotic renal artery stenosis.
Collapse
Affiliation(s)
- Matthew A Corriere
- Department of Vascular and Endovascular Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1095, USA.
| | | | | | | | | | | |
Collapse
|
28
|
Kanjwal K, Haller S, Steffes M, Virmani R, Shapiro JI, Burket MW, Cooper CJ, Colyer WR. Complete versus partial distal embolic protection during renal artery stenting. Catheter Cardiovasc Interv 2009; 73:725-30. [DOI: 10.1002/ccd.21932] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
29
|
Thatipelli MR, Misra S, Sanikommu SR, Schainfeld RM, Sharma SK, Soukas PA. Embolic protection device use in renal artery stent placement. J Vasc Interv Radiol 2009; 20:580-6. [PMID: 19328725 DOI: 10.1016/j.jvir.2009.01.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2008] [Revised: 01/09/2009] [Accepted: 01/11/2009] [Indexed: 10/21/2022] Open
Abstract
PURPOSE The purpose of the present study was to report safety, efficacy, and renal function outcomes with use of the GuardWire embolic protection device (EPD) in renal artery stent placement for patients with renal artery stenosis (RAS) and chronic renal insufficiency (CRI). MATERIALS AND METHODS This was a retrospective study of all patients with RAS and CRI treated concomitantly with a GuardWire EPD and renal artery stents from December 2002 through June 2006. Renal function was determined by calculating the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease formula, and subjects were divided into Kidney Disease Outcomes and Quality Initiative (K-DOQI) classes based on baseline eGFR. After revascularization, an improvement from baseline of at least one K-DOQI class was defined as improvement, unchanged K-DOQI class as stabilization, and worsening of at least one K-DOQI class as deterioration. RESULTS There were 63 patients (54% men) with a mean age of 75.2 years +/- 7.7. The mean baseline serum creatinine level and eGFR were 1.87 mg/dL +/- 0.6 (range, 1-3.8 mg/dL) and 36.63 mL/min per 1.73 m(2) +/- 11.42 (range, 13.85-59.99 mL/min per 1.73 m(2)), respectively, and at the last clinical follow-up, the respective measurements were 1.96 mg/dL +/- 0.72 and 38.75 mL/min per 1.73 m(2) +/- 13.25 (P = not significant). Over a mean follow-up period of 16 months +/- 12, 14 patients (25%) showed improvement, 33 (58%) had stable renal function, and 10 (18%) showed deterioration. There was one GuardWire-related dissection, which was successfully treated with a stent. CONCLUSIONS The GuardWire EPD, used during renal artery stent placement, is safe and was associated with stabilization or improvement in kidney function in 83% of patients with RAS and CRI.
Collapse
|
30
|
Klonaris C, Katsargyris A, Alexandrou A, Tsigris C, Giannopoulos A, Bastounis E. Efficacy of protected renal artery primary stenting in the solitary functioning kidney. J Vasc Surg 2008; 48:1414-22. [DOI: 10.1016/j.jvs.2008.07.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2008] [Revised: 07/12/2008] [Accepted: 07/16/2008] [Indexed: 11/29/2022]
|
31
|
Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Implications of Acute Functional Injury following Percutaneous Renal Artery Intervention. Ann Vasc Surg 2008; 22:783-9. [DOI: 10.1016/j.avsg.2008.06.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2008] [Revised: 06/05/2008] [Accepted: 06/19/2008] [Indexed: 11/30/2022]
|
32
|
Abstract
Renal artery stenosis (RAS) is usually caused by atherosclerosis or fibromuscular dysplasia. RAS leads to activation of the renin-angiotensin-aldosterone system and may result in hypertension, ischemic nephropathy, left ventricular hypertrophy and congestive heart failure. Management options include medical therapy and revascularization procedures. Recent studies have shown angiotensin receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACE-I) to be highly effective in treating the hypertension associated with RAS and in reducing cardiovascular events; however, they do not correct the underlying RAS and loss of renal mass may continue. Renal artery angioplasty was first performed by Gruntzig in 1978. The routine use of stents has increased technical success rates compared with angioplasty, and surgery is now only rarely performed. Although numerous case series claimed benefit in terms of blood pressure control, no adequately powered randomized, controlled, prospective study of renal artery interventions has reported their effect on cardiovascular morbidity or mortality. The CORAL trial, an ongoing study of renal artery stent placement and optimal medical therapy (OMT) funded by the National Institutes of Health, is the first study to attempt to do so. Until the CORAL trial results are in, physicians will continue to be faced with difficult choices when determining the optimal management for RAS patients and deciding which, if any, patients should be offered revascularization.
Collapse
Affiliation(s)
- Gregory J Dubel
- Department of Diagnostic Imaging, Brown University Medical School, Division of Interventional Radiology, Providence, Rhode Island 02903, USA.
| | | |
Collapse
|
33
|
Paraskevas KI, Koutsias S, Mikhailidis DP, Giannoukas AD. Cholesterol Crystal Embolization:A Possible Complication of Peripheral Endovascular Interventions. J Endovasc Ther 2008; 15:614-25. [DOI: 10.1583/08-2395.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Corriere MA, Pearce JD, Edwards MS, Stafford JM, Hansen KJ. Endovascular management of atherosclerotic renovascular disease: early results following primary intervention. J Vasc Surg 2008; 48:580-7; discussion 587-8. [PMID: 18727962 DOI: 10.1016/j.jvs.2008.04.050] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2008] [Revised: 04/15/2008] [Accepted: 04/16/2008] [Indexed: 11/15/2022]
Abstract
OBJECTIVE This retrospective review examines periprocedural morbidity and early functional responses to primary renal artery angioplasty and stenting (RA-PTAS) for patients with atherosclerotic renovascular disease (RVD). METHODS Consecutive patients undergoing primary RA-PTAS for hemodynamically significant atherosclerotic RVD with hypertension and/or ischemic nephropathy were identified from a prospectively maintained registry. Hypertension responses were determined based on pre- and post-intervention blood pressure measurements and medication requirements. Estimated glomerular filtration rate (eGFR) was used to determine renal function responses. Both hypertension and renal function responses were assessed at least three weeks after RA-PTAS. Stepwise multivariable regression analysis was used to examine associations between blood pressure and renal function responses to RA-PTAS and select clinical variables. RESULTS One-hundred ten primary RA-PTAS were performed on 99 patients with atherosclerotic RVD with a mean angiographic diameter-reducing stenosis of 79.2 +/- 12.9%. All patients had hypertension (mean of 3.4 +/- 1.3 antihypertensive agents). Mean pre-intervention eGFR was 49.9 +/- 22.7 mL/min/1.73 m(2), and 74 patients had a pre-intervention eGFR < 60 mL/min/1.73 m(2). The technical success rate for RA-PTAS was 94.5%. The periprocedural complication rate was 5.5%; there were no periprocedural deaths. Statistically significant decreases in mean systolic blood pressure (161.3 +/- 25.2 vs. 148.5 +/- 25.2 post-intervention, P < .0001), diastolic blood pressure (78.6 +/- 13.3 versus 72.5 +/- 13.5 post-intervention, P < .0001), and number of antihypertensive agents (3.3 +/- 1.2 versus 3.1+/- 1.3 post-intervention, P = .009) were observed. Assessed categorically, hypertension response to RA-PTAS was cured in 1.1%, improved in 20.5%, and unchanged in 78.4%. Categorical eGFR response to RA-PTAS was improved in 27.7%, unchanged in 65.1%, and worsened in 7.2%. Multivariable stepwise regression revealed associations between pre- and post-intervention systolic blood pressure (P < .0001), diastolic blood pressure (P < .0001), and eGFR (P < .0001), as well as a trend toward improved diastolic blood pressure response among patients managed with staged bilateral intervention (P = .0589). CONCLUSION Primary RA-PTAS for atherosclerotic RVD was associated with low peri-procedural morbidity and mortality but only modest early improvements in blood pressure and renal function. Results from ongoing prospective trials are needed to assess the long term outcomes associated with RA-PTAS and clarify its role in the management of atherosclerotic RVD.
Collapse
Affiliation(s)
- Matthew A Corriere
- Division of Surgical Sciences, Section on Vascular and Endovascular Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1095, USA
| | | | | | | | | |
Collapse
|
35
|
|
36
|
Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, Safian R, Reddy B, Brewster P, Ankenbrandt MA, Virmani R, Dippel E, Rocha-Singh K, Murphy TP, Kennedy DJ, Shapiro JI, D'Agostino RD, Pencina MJ, Khuder S. Embolic Protection and Platelet Inhibition During Renal Artery Stenting. Circulation 2008; 117:2752-60. [PMID: 18490527 DOI: 10.1161/circulationaha.107.730259] [Citation(s) in RCA: 145] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown.
Methods and Results—
One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease–derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (
P
<0.05), but with combination therapy, it did not decline and was superior to the other allocations in the 2×2 design (
P
<0.01). The main effects of treatment demonstrated no overall improvement in glomerular filtration rate; although abciximab was superior to placebo (0±27% versus −10±20%;
P
<0.05), embolic protection was not (−1±28% versus −10±20%;
P
=0.08). An interaction was observed between abciximab and embolic protection (
P
<0.05), favoring combination treatment. Abciximab reduced the occurrence of platelet-rich emboli in the filters from 42% to 7% (
P
<0.01).
Conclusions—
Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.
Collapse
Affiliation(s)
- Christopher J. Cooper
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Steven T. Haller
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - William Colyer
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Michael Steffes
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Mark W. Burket
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - William J. Thomas
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Robert Safian
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Bhagat Reddy
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Pamela Brewster
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Mary Ann Ankenbrandt
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Renu Virmani
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Eric Dippel
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Krishna Rocha-Singh
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Timothy P. Murphy
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - David J. Kennedy
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Joseph I. Shapiro
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Ralph D. D'Agostino
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Michael J. Pencina
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| | - Sadik Khuder
- From the University of Toledo, Toledo, Ohio (C.J.C., S.T.H., W.C., M.W.B., P.B., M.A.A., D.J.K., J.I.S., S.K.); University of Minnesota, Minneapolis (M.S.); PIMA Cardiovascular, Tucson, Ariz (W.J.T.); William Beaumont Hospital, Royal Oak, Mich (R.S.); Fuqua Heart Center, Atlanta, Ga (B.R.); CVPath Institute, Gaithersburg, Md (R.V.); Midwest Cardiovascular Research, Davenport, Iowa (E.D.); Prairie Cardiovascular, Peoria, Ill (K.R.-S.); Brown University, Providence, RI (T.P.M.); and Boston University,
| |
Collapse
|
37
|
Kaluski E, Tsai S, Klapholz M. Coronary stenting with MGuard: from conception to human trials. CARDIOVASCULAR REVASCULARIZATION MEDICINE 2008; 9:88-94. [DOI: 10.1016/j.carrev.2007.12.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2007] [Revised: 12/03/2007] [Accepted: 12/04/2007] [Indexed: 10/22/2022]
|
38
|
Bates MC, Campbell JE, Broce M, Lavigne PS, Riley MA. Serum Creatinine Stabilization Following Renal Artery Stenting. Vasc Endovascular Surg 2008; 42:40-6. [PMID: 18238866 DOI: 10.1177/1538574407308941] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The impact of renal artery stenting on renal function in a subgroup of consecutive de novo patients with atherosclerotic renal artery stenosis from the single operator, single center, retrospective renal stent trial is defined. Patients with inadequate preprocedure and/or follow-up renal function studies were excluded. Abnormal baseline serum creatinine (sCr) was defined as ≥1.5 mg/dL. Follow-up sCr was improved, unchanged, or worsened if the variance from baseline decreased by >20%, stayed within 20%, or increased >20%, respectively. For the total cohort (194 patients), renal function stabilized or improved in 72% of patients. Plotting 1/sCr demonstrated a decline in renal function before the procedure that stabilized following renal artery stenting. Bilateral renal artery stenting predicted normal follow-up sCr, and baseline sCr >2.1 mg/dL was associated with improvement in sCr long-term. In conclusion, renal artery stenting results in overall stabilization of renal function, and bilateral renal artery stenting seems to have added benefit.
Collapse
Affiliation(s)
- Mark C. Bates
- Vascular Center of Excellence, , Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia
| | - John E. Campbell
- Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia
| | | | - Philip S. Lavigne
- Center for Clinical Sciences Research, Charleston Area Medical Center Research Institute
| | - Mary A. Riley
- Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia
| |
Collapse
|
39
|
Plich M, Klein R. Renal artery stenting with two simultaneous protection devices. Catheter Cardiovasc Interv 2008; 71:264-7. [PMID: 18327846 DOI: 10.1002/ccd.21311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
PURPOSE To describe a new technique for distal protection during stenting of a bifurcated renal artery using two simultaneous filter devices. CASE REPORT A 70-year-old patient underwent angiography of a single functional kidney. Severe proximal, nonostial narrowing of an early bifurcated renal artery was found. Two AngioGuard filter protection devices were placed, one in each branch. A balloon mounted stent was advanced over both wires simultaneously till they reached divergence point, expanded fully, and the protection devices were retrieved. No complications were observed and the final result was good. CONCLUSION The concomitant use of two protection devices is feasible in a particular anatomy context.
Collapse
Affiliation(s)
- Michael Plich
- Invasive Cardiology Unit, Ziv Medical Center, Zefat, Israel
| | | |
Collapse
|
40
|
Dubel GJ, Murphy TP. Distal Embolic Protection for Renal Arterial Interventions. Cardiovasc Intervent Radiol 2007; 31:14-22. [PMID: 17990029 DOI: 10.1007/s00270-007-9211-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2007] [Accepted: 09/11/2007] [Indexed: 10/22/2022]
|
41
|
Abstract
The prevalence of atherosclerotic renal artery stenosis (RAS) is more common than was previously thought, particularly in patients with known coronary, cerebrovascular, or peripheral vascular atherosclerosis. Clinical subsets in which RAS is more common include patients with uncontrolled hypertension, renal insufficiency, and/or sudden onset ("flash") pulmonary edema. Renal artery atherosclerosis progresses over time and is associated with loss of renal function regardless of medical therapy. Patients with symptomatic (hypertension, renal insufficiency, or flash pulmonary edema) and hemodynamically significant RAS are potential candidates for revascularization. The current standard of care is stent placement for aorto-ostial atherosclerotic lesions. Procedure success rates are very high (> or =95%), with infrequent major complication rates. Five-year primary patency rates are 80% to 85%, and secondary patency rates exceed 90%. The key element in managing patients with RAS is selecting those most likely to benefit, that is, those with blood pressure control, preservation or improvement of renal function, and control of flash pulmonary edema from renal revascularization. This article will highlight the anatomical features, physiologic parameters, and biomarkers that may be helpful in optimally selecting patients for renal artery revascularization.
Collapse
Affiliation(s)
- Christopher J White
- Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
| |
Collapse
|
42
|
Edwards MS, Corriere MA, Craven TE, Pan XM, Rapp JH, Pearce JD, Mertaugh NB, Hansen KJ. Atheroembolism during percutaneous renal artery revascularization. J Vasc Surg 2007; 46:55-61. [PMID: 17606122 DOI: 10.1016/j.jvs.2007.03.039] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2006] [Accepted: 03/16/2007] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Atheroembolization during renal artery angioplasty and stenting (RA-PTAS) has been postulated as a cause for the inferior renal function results observed when compared with those with surgical revascularization. To further characterize procedure-associated atheroembolism, we analyzed recovered atheroembolic debris and clinical data from patients undergoing RA-PTAS with distal embolic protection (DEP). METHODS RA-PTAS procedures were performed with DEP using a commercially available temporary balloon occlusion and aspiration catheter system between July 2005 and December 2006. Following RA-PTAS but prior to deflation of the distal occlusion balloon, the static column of blood proximal to the balloon was aspirated and submitted for embolic particle analysis. Angiograms, demographics, and laboratory data were reviewed. Glomerular filtration rate (eGFR) was estimated before RA-PTAS and at 4 to 8 weeks postintervention using the abbreviated Modification of Diet in Renal Disease formula. Associations between clinical factors, captured particle counts, and changes in renal function were examined using univariate techniques and multiple linear regression. RESULTS Twenty-eight RA-PTAS procedures were performed with DEP. Mean total number of embolic particles counted per procedure was 2033 +/- 1553 for particles 20-60 microm and 265 +/- 132 for particles >60 microm. Significant positive associations with quantity of captured particles 20 to 60 microm were observed for African American race (P = .002), predilation (P = .005), and stent diameter (P < .001); a significant negative association was observed for preoperative aspirin use (P =.016). Quantity of captured particles >60 microm was positively associated with ratio of stent to renal artery diameter (P =.009). Change in eGFR was positively associated with preoperative aspirin use (P = .006) and preoperative eGFR (P < .001), while a negative association was observed for captured particle counts >60 microm (P = .015). CONCLUSION These results demonstrate the liberation of thousands of atheroembolic particles during RA-PTAS. Clinical, anatomic, and device-related factors may be predictive of procedural embolization, and increasing captured particle counts >60 microm were associated with inferior renal function results. Further investigation is warranted to establish relationships between atheroembolism, end organ functional impairment, and clinical responses.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Angioplasty, Balloon/adverse effects
- Angioplasty, Balloon/methods
- Blood Pressure
- Creatinine/blood
- Embolism, Cholesterol/blood
- Embolism, Cholesterol/etiology
- Embolism, Cholesterol/pathology
- Embolism, Cholesterol/physiopathology
- Embolism, Cholesterol/prevention & control
- Equipment Design
- Female
- Filtration/instrumentation
- Follow-Up Studies
- Glomerular Filtration Rate
- Humans
- Male
- Particle Size
- Recurrence
- Renal Artery Obstruction/blood
- Renal Artery Obstruction/pathology
- Renal Artery Obstruction/physiopathology
- Renal Artery Obstruction/therapy
- Severity of Illness Index
- Stents
- Time Factors
- Treatment Outcome
- Ultrasonography, Doppler, Duplex
Collapse
Affiliation(s)
- Matthew S Edwards
- Division of Surgical Sciences, Section on Vascular and Endovascular Surgery, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Talenfeld AD, Schwope RB, Alper HJ, Cohen EI, Lookstein RA. MDCT Angiography of the Renal Arteries in Patients with Atherosclerotic Renal Artery Stenosis: Implications for Renal Artery Stenting with Distal Protection. AJR Am J Roentgenol 2007; 188:1652-8. [PMID: 17515390 DOI: 10.2214/ajr.06.1255] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Use of distal protection in renal artery stenting entails overcoming challenges unique to renal artery anatomy. We used 3D image reconstruction to review high-spatial-resolution MDCT angiographic data to better characterize the anatomy of stenotic renal arteries. MATERIALS AND METHODS A total of 218 abdominal MDCT angiograms from a single tertiary care referral center were reviewed. The subjects were 108 patients who had 127 arteries with more than 50% ostial atherosclerotic renal artery stenosis. Vessel analysis software was used to measure renal artery length, cross-sectional area, and maximum diameter. Differences between mean values for women and men and for left and right renal arteries were measured with a two-tailed Student's t test. RESULTS Significant differences for men and women were found in average maximum cross-sectional area distal to the point of stenosis (0.3 +/- 0.19 vs 0.23 +/- 0.09 cm2, p = 0.006) and the corresponding maximum diameter (6.9 +/- 1.7 vs 6.1 +/- 1.1 cm2, p = 0.003). Average lengths of the main renal artery did not differ significantly for men and women. Differences for the left and right main renal arteries were found in minimum area (i.e., area of maximum stenosis, 0.08 +/- 0.04 vs 0.06 +/- 0.03 cm2, p = 0.03), area proximal to the bifurcation (0.26 +/- 0.11 cm2 vs 0.23 +/- 0.07 cm2, p = 0.02), and length (38.5 +/- 12.6 vs 48.7 +/- 16.2 mm, p = 0.0002). CONCLUSION Significant anatomic differences exist between the left and right renal arteries, between the renal arteries in men and those in women, and from one person to the next. Many of these differences are relevant to the design and use of distal protection devices in stenting of the renal arteries.
Collapse
Affiliation(s)
- Adam D Talenfeld
- Division of Interventional Radiology, Mount Sinai Medical Center, One Gustave L. Levy Pl., Box 1234, New York, NY 10029, USA
| | | | | | | | | |
Collapse
|
44
|
Piercy KT, Mostafavi K, Craven TE, Craven BL, Edwards MS, Dean RH, Hansen KJ. Open operative management of dialysis-dependent ischemic nephropathy. ACTA ACUST UNITED AC 2007. [DOI: 10.1002/dat.20118] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
45
|
Invited commentary. J Vasc Surg 2007. [DOI: 10.1016/j.jvs.2006.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|